PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from ...
Retornos totales acumulados hasta el 21/4/2026, que pueden incluir dividendos u otras distribuciones. El punto de referencia es S&P 500 (^GSPC) . Tendencias de las ganancias: INO ...
INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus on Latin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 22, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results